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Summary 
 
 
The Usage of Antibiotics in Bone Surgery 
 
Patrick Tschechne 
 
 
The discovery of antibiotics has drastically changed modern medicine and everyday human life. 
Even though extraordinary discoveries have been made perioperative infections are still commonly 
encountered in clinical practice. Deep infections such as septic arthritis, osteomyelitis and 
periprosthetic joint infections pose great difficulties to practising surgeons and increase the financial 
burden for health care systems across the globe. Multiple antibiotic regimens are commonly used 
where bone surgery is performed. Cephalosporins such as cefazolin are routinely administered in 
surgical theatres around the world, as a measure of prophylaxis to surgical site infections. 
Nevertheless other antibiotics are also frequently indicated. Due to a rise in multidrug-resistant 
micro-organisms worldwide, glycopeptide administration has over time increased markedly. For 
instance vancomycin may nowadays be used in clinical settings where methicillin-resistant Staph. 
aureus (MRSA) is often encountered. Despite existing clinical guidelines, research is still needed to 
keep the surgical community up-to-date during the combat of perioperative infections.  
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1. Introduction 
 
In modern medicine antibiotics are used in everyday clinical practice and play according to medical 
progress an increasingly important role where state-of-the-art bone surgery is performed.  
Not long ago Surgical Site Infection (SSI) has been defined by the united states centre for disease 
control and prevention (CDC) as an “infection, connected to an operative procedure, that occurs at 
or near the site of surgical incision within 30 days of the procedure or within 90 days if prosthetic 
material was implanted“.[1]  
Although for instance in USA surgeons obey elaborated rules of prevention, nosocomial infections 
rank among the ten leading causes of death in the United States of America. Accounting for over 
35% of hospital acquired infections, surgical site infections are the most common cause of 
nosocomial infections. Approximately 2 to 5 % percent of over 30 million surgical patients yearly 
suffer from a SSI. [2, 3]  
This leads to the fact that SSIs can have a remarkable influence on the patients treatment plan and 
are associated with substantial morbidity and mortality increase, higher treatment intensity, higher 
costs and extended length of stay.[4, 5] 
In a paired case-control study of SSI after orthopaedic procedures in the year 2002 it was shown 
that, the median length of stay in the hospital was prolonged by 14 days, re-hospitalization rates 
were doubled, and the total costs were over 300 percent higher.[6] 
 
Looking at those facts, one has to conclude that Antibiotic Administration must be recognized as 
highly influential to the outcome of surgical interventions, whose results can be largely affected by 
postoperative Surgical site infections.[7] So decreasing the rate of postoperative surgical site 
infections [7] by Antibiotic Administration plays a key role in modern surgery.  
Therefore to optimize the progress of modern surgery, we have no alternative but to further 
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investigate antibiotic properties, antibiotic administration and the outcome of treatment regimens as 
well as providing continuous education to every level of clinical professional involved in surgical 
interventions, to reach the decrease in the number of perisurgical infections to a minimum.  
 
In this review an overview of commonly used antibiotics in bone surgery will be given and results 
from published studies will be compared to provide an up-to-date understanding of the 
contemporary perioperative antibiotic regimens.  
It will focus on several essential questions:  
 why antibiotics are administered perioperatively,  
 why certain antibiotic administration is preferred,  
 when antibiotics should be administered,  
 why antibiotic regimens vary in different clinical settings. 
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2. Antibiotics 
 
2.1 History of Antibiotics 
 
In the past medicine possessed no reliable tool against bacterial infections and they were considered 
permanently threatening the lives of humans. Nowadays the discovery and development of 
penicillin and the following antibiotics has changed the general perception and attitude towards 
bacterial infections. 
Nevertheless in modern medicine bacteria are ubiquitous and constantly evolving and this constant 
change in bacterial organisms renders our antibiotic agents over time less effective. 
 
Today one can say that the discovery of antibiotics possibly changed the capacity of modern 
pharmacology and medicine more than any other therapeutic intervention. Through its immense and 
immediate effect on mortality rates it has altered everyday life and human health. 
 
The beginnings of modern pharmacology are marked by Oswald Schmiedeberg (1838-1921), who 
has broadly been accepted as the founder of modern pharmacology. In 1866 Schmiedeberg received 
his medical doctorate at the University of Dorpat, Latvia and thereafter worked in Dorpat under 
Professor Buchheim a well-known scientist at his time. Schmiedeberg then became Professor of 
Pharmacology in 1872 at the University of Strasbourg, where his scientific reputation attracted 
students from many other cities. During his 46 year long stay at the University of Strasbourg, 
Schmiedeberg educated and trained many men that would go on to become professors at other 
German universities. Up to world war II the predominance of the German pharmaceutical industry 
was largely based on Professor Schmiedebergs´ scientific and educational efforts.[8]  
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One of Prof. Schmiedebergs´ main merits was the introduction of experimental pharmacology as a 
biological science. He thereby established the foundation for the development of further 
pharmacological progress.[9] This would ultimately result in contemporary pharmacology including 
the development of antibacterial agents. 
This was the foundation that influenced the way of scientific thinking from that time on and made it 
possible that in 1929 the most important and accidental breakthrough in antibiotic research took 
place. It was a discovery that would change the world, when Sir Alexander Fleming published the 
observation that a penicillium mould inhibits the growth of various bacteria. This discovery is 
widely accepted as the beginning of the modern era of antibacterial drug discovery.[10] 
 
Years after Fleming´s Discovery, Sir Howard Walter Foley and Ernest Boris Chain, decided to 
investigate the clinical potential of penicillin. This ultimately resulted in a shared Nobel Prize for 
Medicine in 1945 for Fleming, Foley and Chain.[11] 
 
From that time on scientists all over the world started to work on the ground prepared by the 
findings of penicillin effects. So the discovery and outstanding effects of penicillin triggered a 
further search for antibiotic producing organisms. Most of the discoveries following penicillin were 
based on soil surveys. The sample collection in Soil surveys is aimed at obtaining a wide variety of 
samples. These samples must then be cultivated and examined for possible antibiotic activity. This 
boost of investigations yielded a wide range of substances.[12] Major natural antibiotics are given 
with the date of discovery in Table 2.1.1 
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Table 2.1.1 : Date of discovery and source of natural antibiotics adapted from Finch, R.G., et al.[13] 
Name Date of discovery Microbe 
Penicillin 
1929–40 
Penicillium notatum 
Tyrothricin 
Gramicidin 
1939 Bacillus brevis 
Tyrocidine 
Griseofulvin 
1939 
1945 
Penicillium griseofulvum 
Dierckx 
Penicillium janczewski 
Streptomycin 1944 Streptomyces griseus 
Bacitracin 1945 Bacillus licheniformis 
Chloramphenicol 1947 Streptomyces venezuelae 
Polymyxin 1947 Bacillus polymyxa 
Framycetin 1947–53 Streptomyces lavendulae 
Chlortetracycline 1948 Streptomyces aureofaciens 
Cephalosporin C, N and P 1948 Cephalosporium sp. 
Neomycin 1949 Streptomyces fradiae 
Oxytetracycline 1950 Streptomyces rimosus 
Nystatin 1950 Streptomyces noursei 
Erythromycin 1952 Streptomyces erythreus 
Oleandomycin 1954 Streptomyces antibioticus 
Spiramycin 1954 Streptomyces ambofaciens 
Novobiocin 1955 
Streptomyces spheroides 
Streptomyces niveus 
Cycloserine 1955 
Streptomyces orchidaceus 
Streptomyces gaeryphalus 
Vancomycin 1956 Streptomyces orientalis 
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Name Date of discovery Microbe 
Rifamycin 1957 Streptomyces mediterranei 
Kanamycin 1957 Streptomyces kanamyceticus 
Nebramycins 1958 Streptomyces tenebraeus 
Paromomycin 1959 Streptomyces rimosus 
Fusidic acid 1960 Fusidium coccineum 
Spectinomycin 1961–62 Streptomyces flavopersicus 
Lincomycin 1962 Streptomyces lincolnensis 
Gentamicin 1963 Micromonospora purpurea 
Josamycin 1964 Streptomyces narvonensisvar.josamyceticus 
Tobramycin 1968 Streptomyces tenebraeus 
Ribostamycin 1970 Streptomyces ribosidificus 
Butirosin 1970 Bacillus circulans 
Sissomicin 1970 Micromonospora myosensis[13] 
Rosaramicin 1972 Micromonospora rosaria 
 
Table 2.1.1 does not represent all the antibiotics discovered but describes most antibiotics to which 
further discoveries were related. 
Interestingly all ensuing marketed antibiotics, at least to the early 2000s, have predominantly been 
semi-synthetic or synthetic derivatives and modifications of pre-existing antibacterial substances. 
Although a great deal of the next-generation agents showed a noteworthy clinical applicability in 
the treatment of bacterial infections, they did not constitute genuinely new mechanistic classes of 
antibiotics. 
A great example for the discovery of antibiotics in the late 1900s is the discovery of azithromycin 
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by a research group of the pharmaceutical company PLIVA in Zagreb, Croatia. In 1981 
azithromycin was patented and had global impact ever since. While azithromycin constituted great 
innovation and applicability, especially due to its slow excretion, it was still a derivative of 
erythromycin.  
The lack of new mechanistic classes during this period proposes that successes in the discovery and 
development of new antibiotic classes have been relatively scarce. 
An explanatory concept to this stagnation is that at times the discovery of large quantities of useful 
antibiotics, during the twentieth century, has been viewed to set an end to the era of demand for new 
antibiotics. This interpretation was based on an extensive decrease in the specific mortality, given 
bacterial infections are the cause of death. 
Nevertheless opinions have changed and at present we know that bacteria are very dynamic 
organisms adapting to environmental influences and resisting xenobiotics, including antibacterial 
agents. This leads to the progressive increase in bacterial resistance to antibiotics commonly used 
nowadays. In fact there is no doubt on the demand of continuous research aiming at the discovery 
and development of new antibacterial agents to be necessary. [14] [15] [16] [17] 
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2.2 Classes of antibiotics commonly used in bone surgery 
2.2.1 β-lactam Antibiotics 
2.2.1.1 Penicillins 
 
As described above Penicillin was discovered by Sir Alexander Fleming in 1929. Penicillin, as well 
as all its derivatives, are comprised of 6-amino-penicillanic-acid (6-APA), which is composed of a 
beta-lactam-ring and thiazolidine. All penicillins act by disruption of the bacterial cell wall.  
The drugs attach to the penicillin-binding proteins on susceptible bacteria and inhibit the enzyme 
transpeptidase. Transpeptidation is the process in which peptide chains are cross-linked within the 
peptidoglycan layer of the bacterial cell wall. The inhibition of transpeptidation leads to instabilities 
in the cell wall and a discrepancy in the hydrolytic processes and processes of cell wall formation. 
These processes are part of the constant remodelling taking place in bacterial cell walls and 
ultimately lead to lysis of the cell by osmotic pressure. 
 
Benzylpenicillin or penicillin G and phenoxymethylpenicillin or penicillin V were the first 
penicillins. These penicillins occurred naturally and are still in clinical use. Main disadvantages of 
benzylpenicillin are β-lactamase-susceptibility and absorptive qualities. Penicillin G shows 
inadequate activity against β-lactamase-producing bacteria. Furthermore penicillin G is poorly 
absorbed through the gastrointestinal tract and therefore has to be administered by injections.[18]  
One direction of scientific work for the further development of Penicillin had the aim to develop 
derivatives of the first penicillins by adding different substituents to the 6-APA. Through these 
processes it was possible to create antibacterials with broader range and higher activity against β-
lactamase-producing-bacteria. 
Broad-spectrum penicillins such as the amino-penicillin amoxicillin possess a wider activity against 
gram negative organisms, such as Salmonella typhi or coli bacteria.[19] 
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The research on isoxazolylpenicillins was driven by clinical problems when staphylococci 
started producing a penicillinase and thereby became resistant to penicillin G and penicillin V. 
An answer to the problem was presented in 1959 when Peter Doyle and John Nayler created 
methicillin which was not inactivated by the penicillinase of staphylococci but showed 
adequate activity against staphylococci. 
The disadvantage of methicillin was that it inconveniently had to be given by injection and 
therefore research continued aiming for a derivative that could be administered orally. The 
synthesis of oxacillin and cloxacillin, which can be administered orally, took place two years 
after the marketing of methicillin and enabled broader use. Modifications to oxacillin and 
cloxacillin then gave rise to dicloxacillin and flucloxacillin with the advantage that if given 
orally dicloxacillin as well as flucloxacillin can produce better concentrations in the 
bloodstream in comparison to their progenitors. [20]     
Today it can be observed that commonly chosen isoxazolylpenicillins in clinical use are oxacillin, 
cloxacillin, dicloxacillin and flucloxacillin. This series of semi-synthetic penicillins possesses acid 
stability and effectiveness against gram-positive bacteria as well as resistance to penicillinase. 
Isoxazolylpenicillins are absorbed when administered per os or by injection and the efficacy is 
significant and established against penicillin-resistant staphylococci, other gram-positive bacteria 
and streptococcal infections. 
The chemical properties and antimicrobial activities are similar for cloxacillin, oxacillin and 
dicloxacillin. However there are differences such as less effectivity of cloxacillin against 
pneumococcal infections and oxacillin´s lower effectivity against penicillin-resistant staphylococcal 
infections, when they are compared to one another.[21] 
 
Generally absorption of penicillins depends on acid stability and adsorption to foodstuff in the gut.  
Penicillins are lipid insoluble and therefore do not enter human cells and cannot cross an intact 
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blood-brain-barrier. Nevertheless penicillins distribute into joints, bile, saliva, breast milk, pleural 
and pericardial spaces. Penicillins even extend across the placenta and can be administered orally, 
with the exception of penicillin G, intravenously and intramuscularly. The elimination of Penicillins 
is predominantly renal. 
 
Regarding the usage of penicillins we can observe that they are still used for sensitive bacteria and 
certain infections. Due to a high degree of bacterial resistance, sensitivity testing may be adequate 
on the individual level with regards to local settings. Penicillins, with regard to sensitivities, are for 
instance still used for bacterial meningitis, bacterial pharyngitis and skin and soft tissue infections. 
Occasionally it may be indicated to start penicillins empirically while laboratory results are pending 
and the probability of penicillin susceptibility is high. 
Adverse effects of penicillins are mainly hypersensitivity reactions, leading to fever as well as 
rashes and must be thought of, if the patient experiences discomfort after drug administration. The 
gastrointestinal flora is also altered if penicillin is given perorally and can lead to gastrointestinal 
complaints and suprainfection for instance by clostridium difficile leading to pseudomembranous 
colitis. Furthermore it has to be kept in mind that anaphylactic shock can occur, granting great 
importance to anamnestic documentation of penicillin allergies.[18]  
 
2.2.1.2 Cephalosporins 
 
According to the Proceedings of the International Consensus Meeting on Periprosthetic Joint 
Infection (PJI) a first or second generation Cephalosporin should be administered for routine 
perioperative surgical prophylaxis.[22] 
Cephalosporins belong to the class of β-lactam antibiotics. The first isolation of cephalosporins was 
made from Cephalosporium fungus. Their biochemical effectiveness results from the fact that 
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Cephalosporins bind to the β-lactam-binding proteins and form covalent bonds with penicillin-
binding proteins. According to this they are capable of inhibiting the last transpeptidation step 
necessary in the synthesis of bacterial cell wall peptidoglycan. 
Nowadays a large amount of different cephalosporins are in clinical use. This includes semi-
synthetic broad-spectrum cephalosporins: 
 second-generation drugs such as cefuroxime,  
 third-generation drugs such as ceftriaxone, cefixime and cefotaxime. 
 
Third generation Cephalosporins have in clinical practice widely replaced first-generation 
cephalosporins such as cefazolin.[18] However in perioperative surgical prophylaxis cefazolin is still 
widely used.[23] 
As a reaction to widespread cephalosporin use, plasmid-encoded and chromosomal β-lactamases 
have led to a higher degree of resistance to cephalosporins. Likewise changes to the membrane 
proteins or mutations in the binding-site proteins can result in diminished drug penetration and 
thereby also cause resistance.   
Cephalosporins are largely given parenterally, intramuscularly as well as intravenously. 
Cephalosporins are in most cases excreted by tubular secretion in the kidney. Although some 
cephalosporins such as ceftriaxone are up to 40% eliminated in the bile. 
Some adverse effects may occur while being treated with cephalosporins. As with penicillins, 
adverse effects have to be monitored and careful documentation of cephalosporin allergy must be 
undertaken. Allergic reactions to cephalosporins have been reported as well as nephrotoxicity and 
drug induced alcohol intolerance. Hypersensitivity reactions resemble allergic reactions to penicillin 
individuals with penicillin allergy are also at higher risk of having allergic reactions to 
cephalosporins. Diarrhoea is another common adverse effect and can be caused by Clostridium 
difficile.[18] 
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2.2.2 Glycopeptides 
 
Vancomycin, possibly the most important representative of the Glycopeptide antibiotics, was 
discovered in the 1950s. Glycopeptides consist of two sugars and an aglycone moiety made of 
heptapeptides. They are produced by the species Streptococcus orientalis and amycolatopsis 
orientalis. Similarly to β-lactam-antibiotics Glycopeptides work by interfering with cell wall 
synthesis. By inhibition of the transglycosylation and transpeptidation, glycopeptides prevent the 
elongation of peptidoglycan and cross-linking. This leads to instabilities in the cell wall similar to 
those produced by penicillins and ultimately leads to cytolysis.  
Glycopeptides are relatively large molecules with a molecular weight of 1500. Due to the size 
glycopeptide antibiotics are unable to penetrate the outer cell membrane of gram-negative bacteria, 
limiting their activity to gram-positive organisms. Likewise they cannot penetrate inside cells, and 
are therefore limited to extracellular targets.[24] 
Teicoplanin is another member of the glycopeptide antibiotic class. 
The activity against gram-positive cocci is heterogeneous even though the basic mode of action is 
the same throughout the glycopeptides. This is mainly due to structural differences outside the 
heptapeptide backbone.[25] Research on these structural differences lead to the development of 
lipoglycopeptides, which show advanced antibacterial activity by dimerization and binding to 
bacterial membranes simultaneously.[26] 
 
Vancomycin itself acts only on dividing cells and relatively slow, if compared in vitro or in vivo 
with penicillin. Additionally vancomycin is not absorbed in the gastrointestinal tract and its only 
oral indication therefore is pseudomembraneous colitis caused by clostridium difficile. Parenteral 
administration is only possible intravenously. It should be considered that vancomycin should be 
administered continuously due to its plasma half-life of about eight hours. If given parenterally 
vancomycin has a wide distribution throughout the body. Teicoplanin, contrary to vancomycin, can 
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be administered once a day and intramuscularly as well as intravenously. 
The most important indications for vancomycin are infections caused by methicillin-resistant 
staphylococci. Most pathogenic, β-lactamase producing staphylococci are susceptible to the action 
of vancomycin. This includes the staphylococci resistant to nafcillin and methicillin. Nevertheless 
Vancomycin is less effective, if compared to traditional treatment, against staphylococci if these are 
susceptible to methicillin. 
Glycopeptides are mainly excreted by the kidney hence clearance of the drug is proportional to 
creatinine clearance and the dosage should be individually calculated if renal clearance is reduced. 
Adverse effects can be seen in about 10% of patients receiving a glycopeptide.  
The majority of adverse effects are minor such as chills and fever. Vancomycin can also lead to 
phlebitis at the site of injection. A more common side effect is the infusion-related flushing due to 
histamine release called the „red man“syndrome. Ototoxicity and nephrotoxicity are serious but rare 
site effects if a glycopeptide is given alone. However the risk of ototoxicity and nephrotoxicity 
increases if other drugs with the same side effects are given simultaneously, for example 
aminoglycosides.[27] 
 
2.2.3 Rifamycin 
 
According to the Proceedings of the International Consensus Meeting on Periprosthetic Joint 
Infection a rifampicin regimen is to be administered in gram-positive PJI.[22] 
Rifampin or rifampicin is a member of the rifamycin antibiotic class. Rifampin is a semi-synthetic 
derivative of rifamycin. Rifamycin is produced by nocardia mediterranei. In Milan, Italy research 
on rifamycins yielded rifampin (N-amino-N´-methylpiperazine) which was introduced into clinical 
use in 1968.[28] [28] 
Rifampin acts by inhibiting RNA synthesis. It binds to the prokaryotic enzyme DNA-dependent 
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RNA polymerase while it cannot bind to the eukaryotic RNA polymerases. Therefore it does not 
affect human transcription. 
Oral administration of rifampin leads to good absorption and a wide distributes through the body, 
spreading through tissues, abscesses and into phagocytic cells. It also spreads readily to body fluids 
leading to orange discolourations of sweat, saliva, sputum, urine and tears as well as spreading to 
the CSF.[18] After being mainly excreted into bile and undergoing enterohepatic circulation, it is 
mostly excreted in faeces. Therefore renal insufficiency has no influence on the dosage.[27] 
Induction of hepatic enzymes, leads to a decrease in half-life during the course of treatment. The 
initial half-life is 1-5 hours. 
Rifampin shows adequate activity against most gram-positive and many gram-negative cocci. Due 
to its ability to enter cells it also shows significant effect on intracellular micro-organisms such as 
mycobacteria and chlamydia. It is therefore a powerful anti-tuberculosis drug. Rifampin is also used 
in combination therapy to eradicate staphylococcal carriage, as well as treatment of staphylococcal 
osteomyelitis.  
Adverse effects are relatively rare. Skin eruptions, fever and gastrointestinal symptoms are most 
frequent. Occasionally rashes, thrombocytopenia or nephritis can be seen. Cholestatic jaundice and 
liver damage was seen in a very small group of patients.  
As a result of hepatic enzyme induction, the degradation of other drugs metabolised in the liver, is 
accelerated. Drugs faster metabolised are for instance glucocorticoids, warfarin, oral anti-diabetics 
and oral contraceptive pills, meaning their oestrogen component. Rifampin is also contraindicated 
during the first trimester of gestation and during lactation.[18, 27] 
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2.2.4 Quinolones 
 
According to the Proceedings of the International Consensus Meeting on Periprosthetic Joint 
Infection fluoroquinolones should be administered in gram-negative PJI.[22] 
 
Quinolones were discovered in 1962 when Lesher et al. accidentaly discovered nalixidic acid as a 
by-product of the chloroquine synthesis. Modifications to the quinolone nucleus gave rise to altered 
antimicrobial activity, most importantly the addition of fluorine allowed penetration into bacterial 
cells and showed activity against staphylococci. Moreover the addition of a cyclopropyl group, gave 
rise to ciprofloxacin, which shows increased activity against gram-positive and gram-negative 
bacteria. 
Quinolones inhibit at least one enzyme of the topoisomerases. Topoisomerases are necessary during 
replication and transcription of DNA. The enzyme group, particularly topoisomerase 2 or DNA 
gyrase, alleviates the strain on DNA strands to enable replication and transcription to proceed. 
By inhibiting these enzymes fluoroquinolones block DNA synthesis and growth of the bacteria 
cannot occur.[29] 
Quinolones are categorized into four generations based on their in vitro activity. The first-
generation shows adequate activity to aerobic, gram-negative bacteria but poor efficacy against 
aerobic, gram-positive bacteria. Nalidixic acid, oxolinic acid, pipedemic acid are some first-
generation quinolones. 
Second-generation quinolones have increased activity against aerobic, gram-positive bacteria and 
against gram-negative bacteria. Introduced in the 1980s, they still showed poor activity against 
anaerobic bacteria. Norfloxacin, the first fluoroquinolone, ciprofloxacin, levofloxacin and 
oflofloxacin are some of the second-generation quinolones. 
Third-generation fluoroquinolones show greater effect on anaerobic bacteria as well as gram-
positive bacteria, especially pneumococci. Grepafloxacin, temafloxacin are some third-generation 
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fluoroquinolones.  
Fourth-generation fluoroquinolones possess higher activity against anaerobes and pneumococci. 
Trovafloxacin, moxifloxacin and clinafloxacin are some fourth-generation fluoroquinolones. 
Fluoroquinolones are still indicated for a great deal of infections, in example ciprofloxacin is 
approved for bone and joint infections, skin and skin-structure infections and numerous other 
infections.[30] 
Adverse effects are rarely seen when fluoroquinolones are given. Most commonly skin rashes, 
nausea, vomiting and diarrhoea have been reported. Fluoroquinolones may lead to arthropathies in 
growing cartilage. Due to inhibition of P450 enzymes ciprofloxacin is seen to have interactions with 
theophylline, which can result in theophylline toxicity.[18] 
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3. Penetrance to bone of antibacterial agents  
 
In the past it was accepted opinion that the majority of antimicrobials produce similar 
concentrations in tissues and plasma, nearly attaining an equilibrium.[31] However some studies 
have shown concentrations at the effect site to differ from the corresponding concentrations 
achieved in serum.[31, 32]   
The antibiotic concentrations measured in bone depend on time and mode of administration, as well 
as the microbiological assay and sample used for measurements. Hence variations can be observed 
in reported values of different studies.[33] 
The diffusion of antibiotics into bone can be subdivided in three classes:  
 
 Good diffusion, being over 30% diffusion. Substances that showed good bone diffusion 
were fluoroquinolones, teicoplanin and rifampin. 
 Moderate diffusion, showing diffusion of 15%-30%. Substances that showed moderate bone 
diffusion were ureidopenicillins, 2nd and 3rd generation cephalosporins and vancomycin  
  Low diffusion into bone tissue, showing less than 15% diffusion. Substances that showed 
low diffusion were penicillin M and first generation cephalosporins.[34]  
 
However cephazolin showed bone concentrations significantly above the minimum bactericidal 
concentrations for Staph. aureus and some gram-negative bacteria.[33]  
Unfortunately guidelines for the research and evaluation of bone penetration studies are still 
needed[35] and moreover a clear association between increased concentrations of antibiotics in bone 
and clinical outcome has not been shown yet.[36]  
Conclusively the choice of antibiotic should be governed by patient, microbiological and surgical 
factors on an individual basis, involving the clinician and the medical microbiologist.[37]   
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4. Current usage of antibiotic treatment in bone surgery 
 
4.1 Routine perioperative surgical prophylaxis 
 
To be optimal, routine surgical prophylaxis should posses certain qualities. Typically these qualities 
include, that:  
Firstly an adequate drug concentration is maintained in the wound, serum and tissue during the 
whole length of operation. Special awareness has to be maintained during the period when the 
incision has not been closed yet and is at risk of bacterial contamination.  
Secondly the antimicrobial agent should be safe for the patient and show adequate activity against 
frequent pathogens encountered in the given type of operation. Whilst showing great activity 
against the probable pathogens, the drug should show lowest possible activity against the normal 
bacterial flora.  
Thirdly the agent should also be carefully chosen with regard to its promotion of bacterial 
resistance.  
Fourthly the economic burden to the hospital and health care system should be taken under 
consideration.[38] 
 
Bearing all these factors in mind common consensus is, that routine perioperative surgical 
prophylaxis should consist of a first- or second-generation cephalosporin, such as cefazolin or 
cefuroxime.[22, 39]  
These drugs possess great activity against the majority of the causative agents for postoperative 
wound infections and a good safety profile.[40] First- and second-generation cephalosporins also 
show excellent distribution in synovium, muscle and bone.[41] In addition more advanced agents and 
treatment regimens of higher cost need to be reserved for upcoming pathogens and drug-resistant 
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micro-organisms.[22] 
The serum half-life of cefazolin is 1.8 hours, with a mean bone concentration of 5.7 micrograms per 
gram of bone and a mean synovial fluid concentration of 24.4 micrograms per millilitre of synovial 
fluid. Minimal bactericidal concentrations are rapidly achieved by these cephalosporins, for covered 
non-MRSA organisms.[42]  
As demonstrated by clinical studies the incidence of deep infections, after hip arthroplasty, can be 
reduced from 3.3% to 0.9% by the administration of cefazolin.[43] 
In another clinical trial, efficacies of three day cefazolin versus one day cefuroxime administration 
were compared. The goal was to determine the impact on postoperative wound infections. 
Ultimately the regimens did not show statistically significant differences.[44, 45]  
In 2009 a study showed that in Scandinavia cloxacillin is most frequently used for surgical 
prophylaxis. It was shown that 99% of Staph. aureus and 80% of coagulase-negative 
Staphylococcus strains, in a cohort study of patients undergoing total joint arthroplasty in Sweden, 
were susceptible to cloxacillin.[46] Thus can be concluded that isoxazolylpenicillins are an 
appropriate alternative to cephalosporins for routine surgical prophylaxis.[22]  
 
Routine surgical prophylaxis should be administered 30 minutes before incision and for the duration 
of one day. Prolonged application of prophylactic antibiotics can promote bacterial resistance and 
lead to higher costs.[47] 
For surgical procedures of long duration additional administration of antibiotics should be 
considered. The duration of surgery as well as blood loss, and fluid resuscitation are factors to 
consider in evaluating re-administration. As a general rule an additional dose of prophylactic 
antibiotic should be administered when the duration of surgery exceeds two half-lives of the 
prophylactic agent.  
Guidelines therefore calculated re-dosing intervals for several antibiotics to be: 
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 every 2 to 5 hours for cefazolin 
 every 3 to 4 hours for cefuroxime 
 every 3 hours for isoxazolylpenicillin 
 every 3 to 6 hours for clindamycin 
 every 6 to 12 hours for vancomycin. 
 
In case of large blood loss the prophylactic agent may be lost in significant quantity, altering 
concentrations to inadequately low levels. Therefore it has been established that an additional dose 
of antibiotic should be given when blood loss is greater than two litres. Similarly changes in drug 
concentration can occur by high volume fluid resuscitation. Intraoperative re-administration of 
antibiotics has been established to be indicated if more than 2 litres of fluid have been given to the 
patient.  
These events should be observed independently and additional doses should be given as soon as one 
parameter is met.[22] 
 
4.2 Alternatives to routine perioperative surgical prophylaxis 
 
If routine prophylaxis cannot be given, a valid option is the usage of vancomycin or teicoplanin. 
Vancomycin has a shorter half-life and shows higher incidences of adverse effects, if compared to 
teicoplanin.[48] Another disadvantage of vancomycin lies in the need of serum monitoring to ensure 
therapeutic concentrations. Furthermore the administration of teicoplanin is less complicated due to 
its prolonged half-life and the option of intramuscular injections. Consequently teicoplanin may be 
an advantageous choice.[49] 
A randomised controlled trial compared the administration of a single IV bolus of teicoplanin with 
the administration of 5 doses of cefazolin in a 24 hour period. Surgical wound infections and 
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adverse effects were observed in both groups and no significant differences were reported.[50] 
Governed by the increasing occurrence of MRSA and methicillin-resistant Staph. epidermidis 
(MRSE) the introduction of glycopeptides, such as teicoplanin and vancomycin, may be reasonable 
in clinical settings with high MRSA and MRSE frequencies.[51] Major drawback of teicoplanin is its 
unavailability in certain countries. 
 
4.3 Prophylaxis in patients with penicillin allergy 
 
A patient undergoing bone surgery with a documented anaphylactic penicillin allergy is to be given 
clindamycin, vancomycin or teicoplanin for surgical prophylaxis. If MRSA rates are low, in the 
specific clinical setting, clindamycin should be preferred if a contraindication such as a true β-
lactam allergy has been established.[22] On the other hand if a non-life threatening penicillin reaction 
is documented cephalosporin may be given. Data suggests cross-reactivities of penicillins and 
cephalosporins to be lower than historically believed, rendering cephalosporins safe for 
prescription.[52] If unsure a skin prick test can be used to evaluate whether the patient has a true β-
lactam allergy. A negative penicillin skin test very clearly establishes that administration of the a β-
lactam is safe at the time of testing.[53] 
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4.4 Surgical prophylaxis in patients with preexisting conditions 
 
4.4.1 Patients with abnormal urinary screening or urinary tract infection 
 
Patients reporting urinary symptoms, prior to planned elective arthroplasty, should undergo urinary 
screening. Urinary screening is indicated, because hematogenous spread of pathogens into the joints 
from a source elsewhere in the body, is a mechanism suggested to be causative of joint infections. 
Urinary symptoms can be classified into obstructive and irritative symptoms. 
Obstructive symptoms, marked by pyuria, should be followed by the consultation of an urologist. 
The consultation is necessary ahead of surgery and delay of surgery should be considered. 
Irritative symptoms such as frequency, urgency and dysuria indicate delay of surgery, if 
concomitantly a bacterial count over 1x103/ml is observed. 
Asymptomatic bacteriuria should not be a reason to delay surgery. These patients should receive 
adequate postoperative oral antibiotics for 8 to 10 days, if the urinary colony count is greater than 
1x103/ml. 
As a measure to decrease postoperative Urinary tract infections a bladder catheter should be 
inserted immediately preoperatively and removed 24 hours after surgery.[54] 
 
4.4.2 Patients with obesity 
 
Preoperative antibiotics need to be weight adjusted. Due to different pharmacokinetics of antibiotics 
in adipose tissue and therefore obese patients doses should be adjusted to the patient’s weight under 
consideration of drug properties. 
Dose amounts should be proportional to the patient weight. Cefazolin dosage for instance should be 
doubled if the patient exceeds 80kg. Therefore patients weighing under 80kg should be given 1 
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gram cefazolin, whereas patients weighing over 80kg should receive 2 grams of cefazolin.[22] It was 
shown that 2 grams of cephazolin provide adequate antibiotic levels for 4 hours even in the morbid 
obese (BMI 40-50kg/m2).[55] Currently the standard recommendation for adults is to administer 2g 
of Cefazolin. 
Clindamycin is recommended to be given in a range of 600-900mg. Dosage of vancomycin, with 
intact kidney function, is recommended to be 10-15mg/kg, but not exceeding 1 gram.  Loading 
doses for vancomycin are calculated on the basis of total body weight and maintenance doses are 
established due to calculated creatinine clearance.[22] 
 
 
4.5 Prophylaxis in patients with previous joint infection and in second-stage 
procedures 
 
Septic arthritis, osteomyelitis and PJI are serious deep infections. If a history of joint infection is 
present in a patient scheduled for orthopaedic surgery, the preoperative antibiotics should be 
adjusted to cover previous causative organisms. Additionally antibiotic laden bone cement should 
be used if a cemented procedure is indicated.[22]  
A matched case control study reported that knees undergoing total knee arthroplasty show 4.1 times 
higher likelihood of additional procedures if the knee was previously infected. It was also 
recommended that patients with evidence of infection less than one year ago should receive a two-
staged procedures for total knee arthroplasty.  
The recommendation to administer 4 to 6 weeks of adequate antibiotic treatment before the second 
procedure was given as well.[56]   The risk of recurrent infection is higher in the particular case of re-
implantation surgery after a two-stage procedure. In 18 patients that had failed the first two-stage 
revision surgeries and underwent another two-stage revision procedure, the same micro-organisms 
as in previous infections were found in 17 patients.[57]  
24 
 
An occurring recurrent infection may be caused by a new infection or by the previous causative 
agent. Therefore coverage of the previous as well as the most common organisms appears logical. 
Furthermore failure of implants has been decreased by antibiotic laden cement in patients with high 
risk.[22] 
There are efforts undertaken to solve periprosthetic joint infections by one-stage instead of two-
stage revision surgeries. One-stage revision would have a clear advantage since it would only 
require one surgical intervention. A prospective study found that total hip arthroplasty revision 
carried out as a one-stage procedure is a valid option. Selection criteria which must be fulfilled prior 
to surgery, are the evidence of minor bone loss and preoperative knowledge of micro-organisms. 
The developed decision tree could potentially decrease overall cost while assuring good standard of 
care.[58] Nevertheless more clinical trials will be needed for widespread acceptance. 
4.6 Antibiotic coverage of war wounds 
 
War settings pose different challenges than organized day-to-day hospital management of injuries. 
War injuries are mainly caused by mine, shell or artillery shrapnel. Therefore foreign material is 
frequently introduced into the wound. Infection may present due to inadequate management, late 
presentation after injury and remaining dead bone in the wound. 
If a bone infection has been diagnosed there are two aspects concerning antimicrobial treatment, 
which need to be considered. On one hand soft tissue must be protected from mainly streptococcal 
and clostridial spread. This is especially true in late presenting injuries that already show signs of 
infection. If adequate wound excision should as well be carried out. On the other hand the antibiotic 
treatment should also prevent recurrence of infection. Nonetheless antibiotic treatment alone is 
insufficient and surgical debridement should be undertaken. All foreign material and dead tissue 
must be removed from the injury site to promote healing. Especially devascularized, dead bone 
fragments can become a reservoir for micro-organisms. Therefore recurrent infections may be 
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caused by dead tissue, particularly by bone left behind at the injury site. Careful evaluation of initial 
procedures should take place. 
 
In circumstances where microbiological investigations are unavailable, the administration of 
benzylpenicillin and metronidazole is adequate. When persistent infection occurs after impeccable 
wound debridement a combination of cloxacillin, metronidazole and gentamicin should be given.  
Dosages should be: 1 gram of cloxacillin every six hours, 1.5 grams of metronidazole should in 
three doses daily and gentamicin should by administered every eight hours with a dose of 80 
milligrams. This regimen is also indicated in patients presenting with signs of evolving sepsis. 
Topical antibiotics, antiseptics and antibiotic-beads are not recommended.[59] 
 
4.7 Antibiotic treatment of open fractures 
 
Open fractures present different problems than common closed fractures. Open fractures always 
imply that a communication to the external environment exists. Consequently there is a higher risk 
for inoculation of micro-organisms. It is generally accepted that open fracture wounds should 
receive emergency treatment, in order to reduce infectious complications. Open fractures are 
classified into 3 types:  
 Type I: Open fracture with a skin wound less than 1 cm long and clean.  
 Type II: Open fracture with a laceration more than 1 cm long without extensive soft tissue 
   damage, flaps, or avulsions.  
 Type III: Either an open segmental fracture, an open fracture with extensive soft  
     tissue damage, or a traumatic amputation.[60]  
 
The organisms contaminating open fracture wounds are of different spectrum than commonly 
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acquired infections in patients undergoing elective surgery. Therefore employed antimicrobial 
regimens should show wider activity against gram-positives and gram-negatives. 
Wound microbiology should also be consulted to choose the appropriate antimicrobial treatment.  
Some parameters putting patients at higher risk of infection are: 
 
 no prophylactic antibiotics administration 
 existence of resistance to antimicrobial regimen 
 long duration from injury to antimicrobial treatment 
 long duration from injury to surgical debridement 
 closure of wound in presence of C. perfringens. 
 
Prophylactic administration of antibiotics is recommended as soon as possible after the injury has 
been sustained. It should cover gram-positives for type 1 and 2 fractures. Type 3 fractures should 
also receive coverage of gram-negatives. For any grade a suspicion of clostridial contamination 
should lead to additional administration of penicillin. Therefore penicillin is generally added to the 
antibiotic regimen. Additionally tetanus prophylaxis should be administered, particularly if the of 
previous vaccination is unclear. The prophylactic antimicrobial should be administered for 24 hours 
in type 1 and 2 fractures and for up to 72 hours for type 3 fractures or for 24 hours after the wound 
has been covered.[61] 
The following table sums up antibiotic agents administered in open fractures: 
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Table 4.7.1 Choice of antibiotic therapy in open fractures [47] 
Fracture Type Recommended antibiotic 
Open type 1 and 2 First generation cephalosporin (Ancef 2g i.v. Loading dose, 1g i.v. Every 8 
hours for 3 doses) 
Open type 3 Third generation cephalosporin or first generation cephalosporin + 
aminoglycoside (gentamicin or tobramicin) 
All open fractures Add penicillin 
Add tetanus prophylaxis 
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5. Conclusion 
 
Since the discovery of antibiotics the perception of infectious diseases has completely changed. 
Joint and bone infections are nowadays treated on a day-to-day basis. In the majority of cases good 
clinical practice of complementary surgical and pharmacological treatment protocols can bring 
relieve to patients. 
Table 5.1. summarizes antibiotic regimens in different clinical conditions: 
 
Table 5.1 Recommended antibiotic regimens for different indications 
 
 
 
Indication Recommended antibiotic regimen 
Standard perioperative 
prophylaxis 
First or second generation Cephalosporin 
Cefazolin 2g or Cefuroxime 1,5g 
 
Timing: 30 minutes before incision for 1 day 
Perioperative prophylaxis in 
patiens with β-lactam allergy 
Clindamycin 900 mg or Vancomycin 15mg/kg 
Perioperative prophylaxis in 
obese patients 
Cefazolin 3g,  if weight > 120kg 
Antibiotic treatment of War 
Wounds 
According to antibiogram 
without microbiology: benzylpenicillin and metronidazole 
1.5g/3xday 
Persistent infection or evolving sepsis: 
cloxacillin 1g/6h ,metronidazole 1.5g/3xday and gentamicin 
80mg/8h 
Antibiotic treatment of open 
fractures 
Type 1/2: Cefazolin 2g i.v. Loading dose,1g i.v./8 hours for 3 doses 
Type 3: Third or first gen. cephalosporin + gentamicin or tobramicin 
+ penicillin 
+tetanus prophylaxis 
29 
 
Table 5.2 summarizes properties of commonly used antibiotics:  
Table 5.2 Properties of antimicrobials used in surgical prophylaxis adapted from Bratzler, D.W., et al.[62] 
Antimicrobial Recommended Dose Half-life in Adults 
with Normal Renal 
Function 
Recommended 
Redosing Interval 
(From Initiation of 
Preoperative Dose) 
Ampicillin-sulbactam 
 
3g (ampicillin 
2g/sulbactam 1g) 
 
0.8–1.3 
 
2 
 
Ampicillin 2g 1–1.9 
 
2 
 
Aztreonam 
 
2g 
 
1.3–2.4 
 
4 
Cefazolin 
 
2 g, 3 g for patients 
weighing ≥120 kg 
 
1.2–2.2 
 
4 
Cefuroxime 
 
1.5g 
 
1–2 
 
4 
Cefotaxime 
 
1 g 
 
0.9–1.7 
 
3 
Cefoxitin 
 
2 g 
 
0.7–1.1 
 
2 
Cefotetan 
 
2 g 
 
2.8–4.6 
 
6 
Ceftriaxone 
 
2 g 
 
5.4–10.9 
 
NA 
 
Ciprofloxacin 
 
400 mg 
 
3–7 
 
NA 
 
Clindamycin 
 
900 mg 
 
2–4 
 
6 
Gentamicin 
 
5 mg/kg based on 
dosing weight (single 
dose) 
 
2–3 
 
NA 
 
Levofloxacin 
 
500 mg 
 
6–8 
 
NA 
 
Metronidazole 
 
500 mg 
 
6–8 
 
NA 
 
Vancomycin 
 
15 mg/kg 
 
4–8 
 
NA 
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When choosing an adequate antimicrobial regimen, the clinician should always abide by the 
standard of choosing the agent which, while being efficient, will be least likely to promote 
resistance. This implies reservation of more powerful antibiotics to multidrug-resistant pathogens. 
Whilst showing great improvement in overall outcome, it is important to point out that 
antimicrobial drugs cannot replace surgical interventions and do not justify a lower standard of 
aseptic technique. 
Some areas investigated around the world are still not unified in the approaches and measurements 
undertaken by researchers. For instance bone penetration is studied by many research teams around 
the world and different methods and materials utilized, lead to difficulties in the interpretation and 
comparison of reported results. Therefore guidelines for the research on bone penetration are still 
needed. 
Even though Guidelines are in place, there are nonetheless multiple areas concerning antimicrobial 
treatment in bone surgery that have to be investigated. For instance globally increasing bacterial 
resistance, represents a problem to routine antibiotic treatment regimes. While efficacy is proven for 
the time being, changes in micro-organisms might render our pharmacological agents of no avail. 
Therefore a need for more research on patterns of evolving bacterial resistance and their 
implementations for future clinical guidelines is essential. Connected to this problem research to 
establish more evidence-based data for upcoming antimicrobials is as well needed. 
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